Clinical Trial Update: Pembrolizumab + Paclitaxel in HR+/HER2- Non-luminal (by PAM50) Advanced Breast Cancer After CDK4/6 Inhibitor Progression [Phase 2]

View source ↗

Summary

A phase 2 trial of pembrolizumab plus paclitaxel in HR+/HER2- non-luminal advanced/metastatic breast cancer after CDK4/6 inhibitor progression was terminated; r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• PACLITAXEL (PACLITAXEL)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: SOLTI Breast Cancer Research Group | Conditions: Metastatic Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2025-06-03